Table 2.
Article | Study Design | Population | Outcome Measures |
---|---|---|---|
Yen, K. et al. (2020) [40] | In vivo study |
C. elegans, Mouse, Human |
Circulating levels of humanin and their relation to diseases of aging and lifespan |
Cai, H. et al. (2021) [72] | Review | N/A | Protective effect of humanin against oxidative stress |
Conte, M. et al. (2019) [30] | In vivo study | Human | Aging; longevity. plasma levels of different mitokines |
Gong, Z. et al. (2022) [49] |
Review | Mouse, Porcine |
Protective effect of humanin in myocardial ischemia-reperfusion. |
Muzumdar, R.H. et al. (2010) [67] | In vivo study | Mouse | Intracardiac administration of a single dose of HNG at the time of ischemia or reperfusion reduces infarction size and improves cardiac function. Humanin attenuated protein levels of Bax in the heart following MI. |
Thummasorn, S. et al. (2016) [68] | In vivo study | Mouse | HNG treatment reduced cardiac infarct size, improved the function of the left ventricle, and decreased cardiac arrhythmias during MI-R. HNG treatment improved cardiac mitochondrial function and decreased the mitochondrial ROS level in cardiac cells |
Sharp, T.E., III et al. (2020) [71] | In vivo study | Porcine | A single dose of HNG, administered at the time of reperfusion, diminishes cardiac infarction size and inhibits cardiomyocyte apoptosis |